Progyny (NASDAQ:PGNY) PT Lowered to $22.00 at JPMorgan Chase & Co.

Progyny (NASDAQ:PGNY) had its target price reduced by JPMorgan Chase & Co. from $31.00 to $22.00 in a report issued on Thursday, Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts also recently issued reports about the stock. Leerink Partnrs downgraded shares of Progyny from a strong-buy rating to a hold rating in a research report on Wednesday, August 7th. Leerink Partners lowered their price objective on shares of Progyny from $25.00 to $21.00 and set a market perform rating on the stock in a research report on Thursday. JMP Securities downgraded shares of Progyny from an outperform rating to a market perform rating in a research note on Thursday. Truist Financial decreased their target price on Progyny from $37.00 to $33.00 and set a buy rating for the company in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald dropped their price target on Progyny from $37.00 to $25.00 and set an overweight rating on the stock in a research report on Thursday. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $27.73.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $16.62 on Thursday. The company has a market capitalization of $1.50 billion, a PE ratio of 27.25, a price-to-earnings-growth ratio of 1.97 and a beta of 1.45. The stock has a fifty day moving average of $24.08 and a 200-day moving average of $28.57. Progyny has a one year low of $13.93 and a one year high of $42.08.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. The business had revenue of $304.09 million during the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. Progyny’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 earnings per share. As a group, research analysts forecast that Progyny will post 0.64 EPS for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, Director Cheryl Scott sold 1,462 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the sale, the director now directly owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Cheryl Scott sold 1,462 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $28.39, for a total transaction of $41,506.18. Following the transaction, the director now owns 10,098 shares in the company, valued at approximately $286,682.22. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Michael E. Sturmer sold 9,030 shares of Progyny stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the completion of the sale, the president now directly owns 362,583 shares of the company’s stock, valued at approximately $10,877,490. The disclosure for this sale can be found here. Corporate insiders own 12.30% of the company’s stock.

Institutional Trading of Progyny

Several large investors have recently made changes to their positions in PGNY. Caprock Group LLC raised its stake in shares of Progyny by 5.3% in the 1st quarter. Caprock Group LLC now owns 6,288 shares of the company’s stock valued at $240,000 after acquiring an additional 319 shares in the last quarter. RiverPark Advisors LLC grew its holdings in Progyny by 9.6% during the second quarter. RiverPark Advisors LLC now owns 5,408 shares of the company’s stock valued at $155,000 after purchasing an additional 474 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Progyny by 2.5% in the first quarter. State of Michigan Retirement System now owns 20,479 shares of the company’s stock valued at $781,000 after purchasing an additional 500 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Progyny by 9.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,260 shares of the company’s stock worth $239,000 after buying an additional 543 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in shares of Progyny by 2.6% in the second quarter. Arizona State Retirement System now owns 24,313 shares of the company’s stock worth $696,000 after buying an additional 609 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.